» Articles » PMID: 18854106

Immature Oocyte Retrieval in the Luteal Phase to Preserve Fertility in Cancer Patients

Overview
Publisher Elsevier
Date 2008 Oct 16
PMID 18854106
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

As cancer treatment outcomes improve, the number of women with cancer seeking fertility preservation increases. Currently, embryo/oocyte cryopreservation appears to provide the best fertility preservation option. However, patients may not have sufficient time to undergo ovarian stimulation prior to chemotherapy and/or the hormones used in ovarian stimulation are contraindicated for certain tumours. In-vitro maturation has been suggested as an effective treatment for these patients. This report presents three women aged 21, 30 and 40 years, without male partners, seeking fertility preservation prior to chemotherapy. They were first seen during the luteal phase of their menstrual cycle and were to undergo gonadotoxic treatment imminently. They underwent immature oocyte retrieval in the luteal phase and seven, five and seven immature oocytes were recovered, respectively. After in-vitro maturation, five, three and five metaphase II (MII) oocytes were vitrified. Two patients later underwent one and two more retrievals, respectively, in the follicular phase of the next cycle(s) and additional oocytes were cryopreserved. These results suggest that immature oocytes recovered in the luteal phase can successfully be matured in vitro; therefore, if there is not sufficient time for conventional follicular-phase oocyte retrieval in a stimulated/unstimulated cycle prior to chemotherapy, a retrieval in the luteal phase could be considered.

Citing Articles

New Insights on In Vitro Maturation of Oocytes for Fertility Preservation.

Gotschel F, Sonigo C, Becquart C, Sellami I, Mayeur A, Grynberg M Int J Mol Sci. 2024; 25(19).

PMID: 39408934 PMC: 11477201. DOI: 10.3390/ijms251910605.


Exploring the Potential of Maturation (IVM) of Oocytes: Indications, Applications, and Treatment Protocols.

Torkashvand H, Shabani R, Amiri I, Darakhshan R, Maleki B, Doostabadi M Avicenna J Med Biotechnol. 2024; 16(3):156-164.

PMID: 39132634 PMC: 11316506. DOI: 10.18502/ajmb.v16i3.15741.


Twenty-first century oocyte cryopreservation-in vitro maturation of immature oocytes from ovarian tissue cryopreservation in cancer patients: A systematic review.

Faizal A, Sugishita Y, Suzuki-Takahashi Y, Iwahata H, Takae S, Horage-Okutsu Y Womens Health (Lond). 2022; 18:17455057221114269.

PMID: 35983837 PMC: 9393350. DOI: 10.1177/17455057221114269.


Potential Use of Immature Oocyte to Improve Fertility Preservation Outcome: A Narrative Review.

Sirait B, Jusuf A, Wiweko B, Handayani N, Aubry D, Muharam R J Hum Reprod Sci. 2022; 15(1):3-11.

PMID: 35494192 PMC: 9053342. DOI: 10.4103/jhrs.jhrs_112_21.


Synergistic Promoting Effects of X-Linked Inhibitor of Apoptosis Protein and Matrix on the In Vitro Follicular Maturation of Marmoset Follicles.

Kim Y, Yun J, Kim S, Kim H, Kang B, Ku S Tissue Eng Regen Med. 2021; 19(1):93-103.

PMID: 34741748 PMC: 8782987. DOI: 10.1007/s13770-021-00387-4.